Harmony Biosciences Files 8-K on Financials

Ticker: HRMY · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1802665

Harmony Biosciences Holdings, INC. 8-K Filing Summary
FieldDetail
CompanyHarmony Biosciences Holdings, INC. (HRMY)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K

Related Tickers: HRMY

TL;DR

Harmony Bio (HRMY) dropped an 8-K detailing financial results and exhibits.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Plymouth Meeting, PA.

Why It Matters

This 8-K filing provides investors with crucial updates on Harmony Biosciences' financial performance and regulatory disclosures, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or significant risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was this 8-K report filed?

The report was filed on January 13, 2025.

What is the principal business address of Harmony Biosciences Holdings, Inc.?

The principal executive offices are located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

What is the SEC File Number for Harmony Biosciences Holdings, Inc.?

The SEC File Number is 001-39450.

Does this filing include any Regulation FD disclosures?

Yes, the filing explicitly lists 'Regulation FD Disclosure' as an item information.

Filing Stats: 892 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-01-13 08:15:13

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, Harmony Biosciences Holdings, Inc. (the "Company") issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2024. In addition, the Company provided guidance related to 2025 net product revenue and provided an update on clinical programs. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference .

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The Company will also be presenting at the 43 rd Annual JP Morgan Healthcare Conference on January 15, 2025. The presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference . The information in this report, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of the federal securities laws. These statements are based on management's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission ("SEC,") on February

01(d). Financial Statements and Exhibits

Item 9.01(d). Financial Statements and Exhibits. The following exhibits are furnished as part of this report on Form 8-K: Exhibit No. Description 99.1 Press release issued by the Company, dated January 13, 2025. 99.2 Harmony Biosciences Holdings, Inc. 43 rd Annual JP Morgan Healthcare Conference Presentation, January 15, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARMONY BIOSCIENCES HOLDINGS, INC. Date: January 13, 2025 By: /s/ Sandip Kapadia Sandip Kapadia Chief Financial Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing